教育和工作經(jīng)歷：

1997.9-2001.6 南開大學(xué)，化學(xué)系，學(xué)士學(xué)位；

2001.8-2001.12 美國(guó)Brandeis大學(xué)，化學(xué)系，博士研究生；

2002.1-2004.8 美國(guó)Texas A&M大學(xué)，化學(xué)系，博士研究生；

2004.9-2006.8 美國(guó)Vanderbilt大學(xué)，化學(xué)生物研究所，博士研究生；

2006.12 美國(guó)Texas A&M大學(xué)，化學(xué)系，博士學(xué)位；

2006.9-2007.10 美國(guó)哈佛大學(xué)醫(yī)學(xué)院, 生物化學(xué)與分子藥理系，博士后；

2007.11-2011.1 美國(guó)哈佛大學(xué)醫(yī)學(xué)院，Dana-Farber 癌癥研究所，博士后；

2011.2-2012.6 美國(guó)國(guó)立衛(wèi)生院/哈佛大學(xué)醫(yī)學(xué)院大規(guī)模細(xì)胞信號(hào)傳導(dǎo)研究中心,研究科學(xué)家；

2012.7-至今 中國(guó)科學(xué)院強(qiáng)磁場(chǎng)科學(xué)中心，研究員；

2013-至今 兼任中國(guó)科學(xué)技術(shù)大學(xué)教授；

迄今已在Nature、Nat Biotech、 Nat Chem Biol、Cancer Cell、Cancer Discovery、Cancer Research、Leukemia、Blood、Chem & Biol、J Med Chem等國(guó)際期刊上發(fā)表 SCI論文47篇，總影響因子412（影響因子大于10的14篇），總引用2400余次，工作多次被F1000, Cancer Cell, Cancer Discovery等專文亮點(diǎn)點(diǎn)評(píng)。參編國(guó)際專著3部；國(guó)際大會(huì)特邀報(bào)告5個(gè)；已獲得國(guó)際授權(quán)專利3項(xiàng)，已申請(qǐng)國(guó)際專利6項(xiàng)、中國(guó)專利9項(xiàng)；國(guó)際市場(chǎng)在售科研用分子探針產(chǎn)品5項(xiàng)，向企業(yè)轉(zhuǎn)移轉(zhuǎn)化專利9項(xiàng)。人社部歸國(guó)留學(xué)人員擇優(yōu)資助、中國(guó)科學(xué)院科技創(chuàng)新“交叉與合作團(tuán)隊(duì)”項(xiàng)目、中科院戰(zhàn)略性科技先導(dǎo)專項(xiàng)子課題一項(xiàng)、國(guó)家自然科學(xué)基金委大科學(xué)裝置聯(lián)合基金重點(diǎn)項(xiàng)目、面上項(xiàng)目、安徽省科技攻關(guān)項(xiàng)目等，參與中科院國(guó)際創(chuàng)新團(tuán)隊(duì)一個(gè)。

學(xué)術(shù)論文

1.“Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia.” H Wu, C Hu, A Wang, E L. Weisberg, Y Chen, C Yun, W Wang, Y Liu, X Liu, B Tian, J Wang, Z Zhao, Y Liang, B Li, L Wang, B Wang, C Chen, S J. Buhrlage, Z Qi, F Zou, A Nonami, Y Li, S M. Fernandes, S Adamia, R M Stone, I A Galinsky, X Wang, G Yang, J D Griffin, J R Brown, M J Eck, J Liu*, N S Gray*, Q Liu*. Leukemia, 2015, Jul 13. doi:10.1038/leu.2015.180. (IF: 10.43)

2.“Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.” H Wu, C Hu, A Wang, E L. Weisberg, W Wang, C Chen, Z Zhao, K Yu, J Liu, J Wu, N Atsushi, L Wang, B Wang, R M Stone, S Liu, J D Griffin, J Liu* and Q Liu*. Leukemia, 2015, Jul 3. doi: 10.1038/leu.2015.175. (IF:10.43)

3.“Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?” Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu*, N S. Gray*, ACS. Chem. Biol, 2014, doi:10.1021/cb500129t. (IF: 5.33)

4.“Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma.”H Wu, W Wang, F Liu, E E. Weisberg, B Tian, Y Chen, B Li, A Wang, B Wang, Z Zhao, D W McMillin, C Hu, H Li, J Wang, Y Liang, S J Buhrlage, J Liang, J Liu, G Yang, J R Brown, S P Treon, C S Mitsiades, J Griffin, Q Liu*, N S Gray* ACS Chem Biol. 2014, DOI: 10.1021/cb4008524. (IF: 5.33)

5.“Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.” Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q*, Lee SW*, Gray NS*. ACS Chem Biol. 2013, 8(10):2145-50. (IF: 5.33)

6.“Discovery of a selective irreversible BMX inhibitor for prostate cancer.” F Liu, X Zhang, EWeisberg, S Chen, W Hur, H Wu, Z Zhao, W Wang, M Mao, C Cai, N I. Simon, T Sanda, J Wang, A. Thomas Look, J D Griffin, S Balk*, Q Liu*, N S Gray*, ACS Chem. Biol., 2013, 8 (7), 1423u20131428. (IF: 5.33)

7.“Developing irreversible inhibitors of the protein kinase cysteinome.” Q Liu, L H. Jones, Y Sabnis, Z Zhao, T Zhang, N S Gray*. Chemistry & Biology, 2013, 20(2):146-59. (IF: 6.64)

8.“Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.” Q Liu, C Xu , S Kirubakaran, X Zhang, W Hur, Y Liu, N P Kwaitkowski, J Wang, K Westover, P Gao, D Erica, C C Thoreen, S A Kang, M P Patricelli, P A Janne, K Wong, D M Sabatini, N S Gray*. Cancer Research, 2013, 73(8):2574-2586. (IF: 9.32)

9.“Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.” E L. Weisberg#, Q Liu#, E Nelson, A L Kung, A L Christie, R Bronson, M Sattler, T Sanda, Z Zhao, W Hur, C Mitsiades, R Smith, J F Daley, R Stone, I Galinsky, J D Griffin, and N S Gray. Leukemia, 2012, 26(10):2233-44. (#Co-first author) (IF: 10.43)

10.“Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.” J Ni#, Q Liu#!, S Xie, C Carlson, T Von, K W Vogel, S M Riddle, C H Benes, M Eck, T M Roberts, N S Gray,* J J Zhao*. Cancer Discovery, 2012, 425-433. (#Co-first author) (IF: 19.45)